Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors

por Kirkham, Bruce, Sesin, Carlos, Gellett, Amanda M., Sprabery, Aubrey T., Lin, Chen-Yen, Turkiewicz, Anthony
Publicado 2021

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure

por Deodhar, Atul A, Combe, Bernard, Accioly, Ana P, Bolce, Rebecca, Zhu, Danting, Gellett, Amanda M, Sprabery, Aubrey Trevelin, Burmester, Gerd-Rüdiger R
Publicado 2022

Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials

por Eder, Lihi, Tony, Hans-Peter, Odhav, Satish, Agirregoikoa, Eva Galindez, Korkosz, Mariusz, Schwartzman, Sergio, Sprabery, Aubrey Trevelin, Gellett, Amanda M., Park, So Young, Bertram, Clinton C., Ogdie, Alexis
Publicado 2022

Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study

por Smolen, Josef S., Sebba, Anthony, Ruderman, Eric M., Schulze-Koops, Hendrik, Sapin, Christophe, Gellett, Amanda M., Sprabery, Aubrey Trevelin, Li, Lingnan, de la Torre, Inmaculada, Gallo, Gaia, Liu-Leage, Soyi, Pillai, Sreekumar, Reis, Paulo, Nash, Peter
Publicado 2020

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)

por Orbai, Ana-Maria, Gratacós, Jordi, Turkiewicz, Anthony, Hall, Stephen, Dokoupilova, Eva, Combe, Bernard, Nash, Peter, Gallo, Gaia, Bertram, Clinton C., Gellett, Amanda M., Sprabery, Aubrey Trevelin, Birt, Julie, Macpherson, Lisa, Geneus, Vladimir J., Constantin, Arnaud
Publicado 2020